Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Abrocitinib

FDA-approved product (tablet, oral), marketed as Cibinqo.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Abrocitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atopic eczema
  • Eczematoid dermatitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Agents for dermatitis, excluding corticosteroids
FDA pharmacologic class
Janus Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA34.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli30.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae17.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Abrocitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Abrocitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

    NCT02201524 · start 2014-11

    Registered record
    Registry ID
    NCT02201524
    Conditions
    Plaque Psoriasis
    Interventions
    PF-04965842; PF-04965842; PF-04965842; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-11
    Completion
    2015-09
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Psoriasis
    InterventionPF-04965842; PF-04965842; PF-04965842; Placebo
    PhasePhase 2
    Registry statusTerminated

  • AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy Subjects

    NCT02163161 · start 2014-06

    Registered record
    Registry ID
    NCT02163161
    Conditions
    Healthy
    Interventions
    PF-04965842; PF-04965842; PF- 04965842
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-06
    Completion
    2014-08
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPF-04965842; PF-04965842; PF- 04965842
    PhasePhase 1
    Registry statusCompleted

  • First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects

    NCT01835197 · start 2013-05

    Registered record
    Registry ID
    NCT01835197
    Conditions
    Healthy
    Interventions
    PF-04965842; Placebo; PF-04965842; Placebo; PF-04965842; Placebo; PF-04965842; Placebo; PF-04965842; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-05
    Completion
    2014-06
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPF-04965842; Placebo; PF-04965842; Placebo +6 more
    PhasePhase 1
    Registry statusCompleted

  • Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis

    NCT04564755

    Registered record
    Registry ID
    NCT04564755
    Conditions
    Atopic Dermatitis
    Interventions
    abrocitinib
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    Interventionabrocitinib
    PhaseNot recorded
    Registry statusNo longer available

  • Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)

    NCT05466578

    Registered record
    Registry ID
    NCT05466578
    Conditions
    Severe Uncontrolled Atopic Dermatitis
    Interventions
    abrocitinib
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Uncontrolled Atopic Dermatitis
    Interventionabrocitinib
    PhaseNot recorded
    Registry statusAvailable